Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: A type II isobolographic analysis

Epilepsy Research

Volumn 98, Issue 2-3, 2012, Pages 148-156

  Luszczki, Jarogniew J ^a,b   Filip, Damian ^a   Florek Luszczki, Magdalena ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Interaction; Isobolographic analysis; Maximal electroshock; Pregabalin

Indexed keywords

ETIRACETAM; GABAPENTIN; PREGABALIN; TIAGABINE; VIGABATRIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; DRUG RETENTION; ELECTRIC SHOCK; ELECTRODE; GRIP STRENGTH; LONG TERM MEMORY; MALE; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; SEIZURE; SKELETAL MUSCLE; STIMULUS RESPONSE; TONIC SEIZURE;

AMINES; ANIMALS; ANTICONVULSANTS; AVOIDANCE LEARNING; CONFIDENCE INTERVALS; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTROSHOCK; GAMMA-AMINOBUTYRIC ACID; HAND STRENGTH; MALE; MICE; MOTOR ACTIVITY; PIRACETAM; SEIZURES; VIGABATRIN;

EID: 84856509036     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.09.002     Document Type: Article

References (56)

1. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004, 45(Suppl. 6):13-18.
2. Bernasconi R., Klein M., Martin P., Christen P., Hafner T., Portet C., Schmutz M. Gamma-vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice. J. Neural Transm. 1988, 72:213-233.
3. 2+ channels via GABAB receptors in hippocampal pyramidal cells. Synapse 2003, 50:95-109.
4. Bian F., Li Z., Offord J., Davis M.D., McCormick J., Taylor C.P., Walker L.C. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 2006, 1075:68-80.
5. Bockbrader H.N., Burger P., Knapp L. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia 2011, 52:405-409.
6. Bockbrader H.N., Burger P., Knapp L., Corrigan B.W. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia 2011, 52:248-257.
7. Bockbrader H.N., Wesche D., Miller R., Chapel S., Janiczek N., Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin. Pharmacokinet. 2010, 49:661-669.
8. Boissier J.R., Tardy J., Diverres J.C. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med. Exp. (Basel) 1960, 3:81-84.
9. Brodie M.J. Pregabalin as adjunctive therapy for partial seizures. Epilepsia 2004, 45(Suppl. 6):19-27.
10. Chen L., Yung W.H. Effects of the GABA-uptake inhibitor tiagabine in rat globus pallidus. Exp. Brain Res. 2003, 152:263-269.
11. 2+ channels, KATP channels or N-methyl-d-aspartic acid receptors?. Anesth. Analg. 2006, 102:182-187.
12. Czuczwar S.J., Patsalos P.N. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001, 15:339-350.
13. Deckers C.L.P., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., Patsalos P.N., Renier W.O., Van Rijn C.M. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000, 41:1364-1374.
14. +-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002, 45:171-190.
15. 2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol. Sci. 2007, 28:75-82. Erratum in: Trends Pharmacol. Sci. 28, 151 (2007).
16. Elger C.E., Brodie M.J., Anhut H., Lee C.M., Barrett J.A. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005, 46:1926-1936.
17. Engelborghs S., Pickut B.A., D'Hooge R., Wiechert P., Haegele K., De Deyn P.P. Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats. Arzneimittelforschung 1998, 48:713-716.
18. French J.A., Kugler A.R., Robbins J.L., Knapp L.E., Garofalo E.A. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003, 60:1631-1637.
19. Gale K. Binding of [3H]gamma-vinyl-GABA to GABA-transaminase in brain homogenates. Life Sci. 1984, 34:701-706.
20. Gillard M., Chatelain P., Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur. J. Pharmacol. 2006, 536:102-108.
21. Goldlust A., Su T.Z., Welty D.F., Taylor C.P., Oxender D.L. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res. 1995, 22:1-11.
22. Hutson S.M., Berkich D., Drown P., Xu B., Aschner M., LaNoue K.F. Role of branched-chain aminotransferase isoenzymes and gabapentin in neurotransmitter metabolism. J. Neurochem. 1998, 71:863-874.
23. Jackson M.F., Esplin B., Capek R. Activity-dependent enhancement of hyperpolarizing and depolarizing gamma-aminobutyric acid (GABA) synaptic responses following inhibition of GABA uptake by tiagabine. Epilepsy Res. 1999, 37:25-36.
24. Klitgaard H., Matagne A., Gobert J., Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998, 353:191-206.
25. Larsson O.M., Gram L., Schousboe I., Schousboe A. Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes. Neuropharmacology 1986, 25:617-625.
26. Leach J.P. Antiepileptic drugs: safety in numbers?. Seizure 2000, 9:170-178.
27. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949, 96:99-113.
28. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011, 20:359-368.
29. Löscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991, 8:79-94.
30. Löscher W., Hönack D., Taylor C.P. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci. Lett. 1991, 128:150-154.
31. Löscher W., Jäckel R., Müller F. Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model. Eur. J. Pharmacol. 1989, 163:1-14.
32. Löscher W., Wauquier A. Use of animal models in developing guiding principles for polypharmacy in epilepsy. Epilepsy Res. 1996, (Suppl. 11):61-65.
33. Luszczki J.J. Additive interaction of pregabalin with phenytoin in the mouse maximal electroshock-induced seizure model: an isobolographic analysis. Ann. UMCS Sect. DDD 2009, 22:31-38.
34. Luszczki J.J. Interactions between pregabalin and phenobarbital in the mouse maximal electroshock-induced seizure model: an isobolographic analysis. J. Pre-Clin. Clin. Res. 2009, 3:103-109.
35. Luszczki J.J. Interaction of pregabalin with carbamazepine in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. Adv. Med. Sci. 2010, 55:1-10.
36. Luszczki J.J., Andres M.M., Czuczwar P., Cioczek-Czuczwar A., Ratnaraj N., Patsalos P.N., Czuczwar S.J. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia 2006, 47:10-20.
37. Luszczki J.J., Andres M.M., Czuczwar S.J. Synergistic interaction of gabapentin and oxcarbazepine in the mouse maximal electroshock seizure model - an isobolographic analysis. Eur. J. Pharmacol. 2005, 515:54-61.
38. Luszczki J.J., Andres-Mach M.M., Ratnaraj N., Patsalos P.N., Czuczwar S.J. Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia 2007, 48:806-815.
39. Luszczki J.J., Antkiewicz-Michaluk L., Czuczwar S.J. Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol. 2009, 602:298-305.
40. Luszczki J.J., Czuczwar S.J. Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369:434-446.
41. Luszczki J.J., Filip D., Czuczwar S.J. Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. Epilepsy Res. 2010, 91:166-175.
42. Luszczki J.J., Wojcik-Cwikla J., Andres M.M., Czuczwar S.J. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology 2005, 30:958-973.
43. Meldrum B.S., Chapman A.G. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia 1999, 40(Suppl. 9):S2-S6.
44. Meyer O.A., Tilson H.A., Byrd W.C., Riley M.T. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav. Toxicol. 1979, 1:233-236.
45. Micheva K.D., Taylor C.P., Smith S.J. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol. Pharmacol. 2006, 70:467-476.
46. Pisani A., Bonsi P., Martella G., De Persis C., Costa C., Pisani F., Bernardi G., Calabresi P. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004, 45:719-728.
47. Porreca F., Jiang Q., Tallarida R.J. Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur. J. Pharmacol. 1990, 179:463-468.
48. Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., Leprince P., Moonen G., Selak I., Matagne A., Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br. J. Pharmacol. 2002, 136:659-672.
49. Sills G.J. The mechanisms of action of gabapentin and pregabalin. Curr. Opin. Pharmacol. 2006, 6:108-113.
50. h in rat CA1 pyramidal cells. Epilepsia 2003, 44:150-156.
51. Suzdak P.D., Jansen J.A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995, 36:612-626.
52. Taylor C.P., Angelotti T., Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007, 73:137-150.
53. Taylor C.P., Gee N.S., Su T.Z., Kocsis J.D., Welty D.F., Brown J.P., Dooley D.J., Boden P., Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998, 29:233-249.
54. Tomson T., Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin. Pharmacokinet. 2007, 46:209-219.
55. Vartanian M.G., Radulovic L.L., Kinsora J.J., Serpa K.A., Vergnes M., Bertram E., Taylor C.P. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 2006, 68:189-205.
56. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., Rossier J. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature 1986, 321:864-866.